We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+12.69%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$11B
AUM Growth
+$1.14B
Cap. Flow
+$217M
Cap. Flow %
1.96%
Top 10 Hldgs %
40.32%
Holding
138
New
6
Increased
33
Reduced
26
Closed
8

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$152M
2
GILD icon
Gilead Sciences
GILD
+$129M
3
WCG
Wellcare Health Plans, Inc.
WCG
+$102M
4
PBYI icon
Puma Biotechnology
PBYI
+$81.9M
5
ESRX
Express Scripts Holding Company
ESRX
+$72M

Top Sells

Rank Stock Value
1
MOH icon
Molina Healthcare
MOH
+$168M
2
SHPG
Shire pic
SHPG
+$85.9M
3
MCK icon
McKesson
MCK
+$66.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$66.1M
5
COO icon
Cooper Companies
COO
+$55.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.58%
2 Financials 0.18%
3 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
51
DELISTED
Dynavax Technologies
DVAX
$59.7M 0.54%
2,472,200
– –
SHPG
52
DELISTED
Shire pic
SHPG
$51.4M 0.47%
250,971
-413,429
-62% -$85.9M
OTIC
53
DELISTED
Otonomy, Inc.
OTIC
$51.3M 0.46%
1,850,094
-406,304
-18% -$10.1M
MDT icon
54
Medtronic
MDT
$111B
$45.3M 0.41%
588,299
– –
ARRY
55
DELISTED
Array Biopharma Inc
ARRY
$45.1M 0.41%
10,689,000
+628,500
+6% +$2.87M
CI icon
56
Cigna
CI
$79.6B
$41.3M 0.37%
+282,000
New +$38.8M
CERS icon
57
Cerus
CERS
$585M
$41.1M 0.37%
6,504,400
– –
BHC icon
58
Bausch Health
BHC
$1.69B
$39.6M 0.36%
390,000
+225,000
+136% +$25.3M
LUMO
59
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$34.8M 0.31%
106,145
+27,000
+34% +$8.79M
INFI
60
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$34.7M 0.31%
4,416,300
– –
MOH icon
61
Molina Healthcare
MOH
$10.5B
$34.2M 0.31%
568,850
-2,667,450
-82% -$168M
AFMD
62
DELISTED
Affimed
AFMD
$32.6M 0.3%
458,262
– –
XNPT
63
DELISTED
XENOPORT, INC.
XNPT
$31.7M 0.29%
5,768,400
– –
JNJ icon
64
Johnson & Johnson
JNJ
$643B
$30M 0.27%
292,000
– –
SRRA
65
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$29.9M 0.27%
49,749
– –
UNH icon
66
UnitedHealth
UNH
$389B
$28M 0.25%
238,000
– –
LAB icon
67
Standard BioTools
LAB
$311M
$26.5M 0.24%
2,449,900
– –
CLVS
68
DELISTED
Clovis Oncology, Inc.
CLVS
$25.5M 0.23%
729,600
-376,300
-34% -$24.3M
GWPH
69
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$21.1M 0.19%
304,100
-73,000
-19% -$5.95M
PRQR icon
70
ProQR Therapeutics
PRQR
$248M
$19.7M 0.18%
2,271,500
+430,100
+23% +$4.95M
FWP
71
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$18.3M 0.17%
137,229
– –
CYNA
72
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$17.6M 0.16%
1,140,325
– –
SYK icon
73
Stryker
SYK
$133B
$17.3M 0.16%
186,000
– –
ENTA icon
74
Enanta Pharmaceuticals
ENTA
$367M
$16.7M 0.15%
+504,300
New +$16.4M
PVLA
75
Palvella Therapeutics
PVLA
$2.05B
$16.6M 0.15%
90,745
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2015 Portfolio in Review

As of Q4 2015, OrbiMed held 138 positions worth $11B, up 11% from $9.91B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q4 2015 filing shows 6 new, 33 increased, 26 reduced and 8 closed positions. Its largest new stake was Viatris: 3,157,000 shares worth $171M. The largest sale was Molina Healthcare, an estimated $168M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q4 2015 buy was Viatris: 3,157,000 shares worth $171M.
  • OrbiMed added most to Gilead Sciences in Q4 2015, an estimated $129M increase.
  • OrbiMed's biggest Q4 2015 reduction was Molina Healthcare, cutting an estimated $168M.
  • OrbiMed fully exited Chimerix, Inc. in Q4 2015, selling an estimated $39M.
  • OrbiMed's ten largest holdings make up 40% of its $11B portfolio in Q4 2015.
  • OrbiMed opened 6 new positions and closed 8 in Q4 2015.
  • OrbiMed's portfolio value rose 11% quarter-over-quarter to $11B.

Based on OrbiMed's 13F filing for Q4 2015, filed 16 Feb 2016.